Legal & General Group
MLYS icon

Legal & General Group’s Mineralys Therapeutics MLYS Stock Holding History

Legal & General Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Sell
38,050
-423
-1% -$11.6K ﹤0.01% 2191
2026
Q1 		$1.04M Sell
38,473
-5,465
-12% -$160K ﹤0.01% 2132
2025
Q4 		$1.59M Sell
43,938
-1,491
-3% -$59.8K ﹤0.01% 2067
2025
Q3 		$1.72M Buy
45,429
+9,380
+26% +$203K ﹤0.01% 2041
2025
Q2 		$488K Buy
36,049
+33,467
+1,296% +$485K ﹤0.01% 2450
2025
Q1 		$41K Hold
2,582
– – ﹤0.01% 2753
2024
Q4 		$31.8K Hold
2,582
– – ﹤0.01% 2869
2024
Q3 		$31.2K Hold
2,582
– – ﹤0.01% 2884
2024
Q2 		$30.2K Buy
2,582
+900
+54% +$11.3K ﹤0.01% 2878
2024
Q1 		$21.7K Hold
1,682
– – ﹤0.01% 2928
2023
Q4 		$14.5K Buy
1,682
+489
+41% +$3.84K ﹤0.01% 3156
2023
Q3 		$11.4K Sell
1,193
-251
-17% -$3.27K ﹤0.01% 3243
2023
Q2 		$24.7K Buy
1,444
+171
+13% +$2.56K ﹤0.01% 3023
2023
Q1 		$19.9K Buy
+1,273
New +$21.4K ﹤0.01% 3069

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Legal & General Group's MLYS Position: Q2 2026 in Review

Legal & General Group reduced its Mineralys Therapeutics (MLYS) stake by 1.1% in Q2 2026, selling an estimated $11.6K and leaving 38,050 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2191.

Legal & General Group first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.72M in Q3 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Legal & General Group held 38,050 shares of Mineralys Therapeutics worth $1.03M as of Q2 2026.
  • Legal & General Group sold 423 Mineralys Therapeutics shares in Q2 2026, an estimated $11.6K.
  • Mineralys Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2191 holding.
  • Legal & General Group first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Legal & General Group's Mineralys Therapeutics position peaked at $1.72M in Q3 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.